Repligen (RGEN) Downgraded by BidaskClub

BidaskClub downgraded shares of Repligen (NASDAQ:RGEN) from a strong-buy rating to a buy rating in a research report released on Tuesday, September 25th.

A number of other analysts have also recently commented on the company. JPMorgan Chase & Co. boosted their price target on Repligen to $60.00 and gave the stock an overweight rating in a research report on Monday, September 24th. Zacks Investment Research cut Repligen from a hold rating to a sell rating in a research report on Tuesday, August 7th. Citigroup boosted their price target on Repligen from $45.00 to $56.00 and gave the stock a buy rating in a research report on Friday, July 20th. Stephens boosted their price target on Repligen from $50.00 to $55.00 and gave the stock an average rating in a research report on Tuesday, July 10th. Finally, ValuEngine raised Repligen from a hold rating to a buy rating in a research report on Thursday, June 28th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of $51.86.

Repligen stock opened at $54.01 on Tuesday. The company has a market cap of $2.43 billion, a price-to-earnings ratio of 78.28, a PEG ratio of 4.46 and a beta of 0.69. Repligen has a fifty-two week low of $29.56 and a fifty-two week high of $58.99.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported $0.16 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.18 by ($0.02). Repligen had a net margin of 13.49% and a return on equity of 5.05%. The firm had revenue of $47.73 million for the quarter, compared to the consensus estimate of $45.84 million. During the same period in the previous year, the firm posted $0.20 earnings per share. The business’s revenue was up 47.0% compared to the same quarter last year. On average, equities research analysts anticipate that Repligen will post 0.71 earnings per share for the current year.

In other news, major shareholder Roy T. Eddleman sold 4,770 shares of the company’s stock in a transaction on Wednesday, August 8th. The stock was sold at an average price of $49.05, for a total value of $233,968.50. Following the completion of the sale, the insider now directly owns 413,985 shares in the company, valued at approximately $20,305,964.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Roy T. Eddleman sold 33,142 shares of the company’s stock in a transaction on Monday, August 6th. The stock was sold at an average price of $49.05, for a total value of $1,625,615.10. Following the completion of the sale, the insider now owns 413,985 shares of the company’s stock, valued at $20,305,964.25. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 88,884 shares of company stock valued at $4,693,683. Company insiders own 1.40% of the company’s stock.

Several large investors have recently bought and sold shares of the company. SG Americas Securities LLC bought a new position in Repligen in the 2nd quarter worth $135,000. Smith Asset Management Group LP boosted its holdings in Repligen by 1,511.8% in the 2nd quarter. Smith Asset Management Group LP now owns 4,658 shares of the biotechnology company’s stock worth $219,000 after buying an additional 4,369 shares during the period. Benin Management CORP bought a new position in Repligen in the 2nd quarter worth $235,000. GSA Capital Partners LLP bought a new position in Repligen in the 2nd quarter worth $250,000. Finally, Victory Capital Management Inc. boosted its holdings in Repligen by 38.9% in the 1st quarter. Victory Capital Management Inc. now owns 5,755 shares of the biotechnology company’s stock worth $208,000 after buying an additional 1,612 shares during the period. Hedge funds and other institutional investors own 92.50% of the company’s stock.

About Repligen

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Recommended Story: Do Tariffs Work?

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply